Skip to main content
Menu
US
oncology-evaluation1920
Application Note

CDK signaling in oncology: evaluate phosphorylation events trigged by DNA damage

DNA double-strand breaks, like those induced by the widely used chemotherapy drug etoposide, trigger a DNA damage response that activates a variety of repair mechanisms, including the phosphorylation of the histone protein component H2AX. DNA damage can directly affect cell cycle progression by modulating levels of an important cell cycle regulator – cyclin-dependent kinase 1 (CDK1).

In this application note, you will learn how to:

  • Evaluate DNA damage induced by etoposide treatment using phosphorylated (Ser139) histone H2AX as a biomarker for the detection of DNA double-strand breaks
  • Utilize AlphaLISASureFire® Ultra™ technology to characterize changes in crucial cell cycle events by measuring both phospho- and total target proteins from the same cell lysate sample

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

Download Resource

CDK signaling in oncology: evaluate phosphorylation events trigged by DNA damage